companydata.dkACESION PHARMA ApS: Financial statements 2016
CVR: 34083738
ACESION PHARMA ApS (CVR 34083738) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -14,393,708 and a net result of DKK -18,262,257 compared with DKK -9,804,270 the year before. Equity amounted to DKK 14,054,330. The solvency ratio was 35.3%.
- Gross Profit
- -14,393,708 kr.
- Profit/Loss
- -18,262,257 kr.
- Equity
- 14,054,330 kr.
- Total Assets
- 39,785,907 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | -14.4 mio. | -18.3 mio. | 14.1 mio. | - |
| 2015 | - | -8.5 mio. | -9.8 mio. | 1.5 mio. | - |
| 2014 | - | -4.7 mio. | -6.5 mio. | 3.8 mio. | - |
| 2013 | - | -4.8 mio. | -6.5 mio. | -556 t. | - |
| 2012 | - | -1.3 mio. | -2.1 mio. | 2 mio. | - |
How creditworthy is ACESION PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2016
ACESION PHARMA ApS has published its annual report for 2015. Gross profit came to DKK -8,496,428, and the net result was DKK -9,804,270.
As of May 2, 2016, Morten Grunnet has stepped down as director of ACESION PHARMA ApS.
As of April 1, 2016, Frans Gustaf Wuite is registered as adm. dir. of ACESION PHARMA ApS.
As of April 1, 2016, Ulrik Svane Sørensen has stepped down as adm. dir. of ACESION PHARMA ApS.
As of February 1, 2016, Paul David Goldenheim has joined the board of directors of ACESION PHARMA ApS.
As of February 1, 2016, Carsten Schou has left the board of directors of ACESION PHARMA ApS.
About ACESION PHARMA ApS
ACESION PHARMA ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Gaarsdal Holst. The company's owners include Novo Holdings A/S, Canaan XII L.P. and Alpha Wave Ventures II, LP. The company has 14 employees. In 2025, the company reported a net result of DKK -59,597,000 compared with DKK -43,033,000 the year before. Equity amounted to DKK 276,067,000.